Atossa Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: ATOS · Form: 8-K · Filed: May 12, 2025 · CIK: 1488039

Atossa Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAtossa Therapeutics, INC. (ATOS)
Form Type8-K
Filed DateMay 12, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: shareholder-vote, corporate-governance, filing

Related Tickers: ATOS

TL;DR

ATOS filed an 8-K for a shareholder vote. Keep an eye on the outcome.

AI Summary

Atossa Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting on a submission of matters to a vote of security holders. The earliest event reported was on May 8, 2025. The company is incorporated in Delaware and headquartered in Seattle, Washington.

Why It Matters

This filing indicates that Atossa Therapeutics is engaging in a process that requires shareholder approval, which could impact corporate governance and future strategic decisions.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can sometimes precede significant corporate actions or changes that may affect stock price.

Key Numbers

Key Players & Entities

FAQ

What specific matters are being submitted to a vote of security holders?

The filing states 'Submission of Matters to a Vote of Security Holders' as the item information, but the specific details of the matters are not provided in this excerpt.

When was the earliest event reported in this filing?

The earliest event reported was on May 8, 2025.

What is Atossa Therapeutics, Inc.'s principal executive office address?

The principal executive offices are located at 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.

What is the company's IRS Employer Identification Number?

The IRS Employer Identification Number is 26-4753208.

What is the SEC file number for Atossa Therapeutics, Inc.?

The SEC file number is 001-35610.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding ATOSSA THERAPEUTICS, INC. (ATOS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing